Our findings of a low ratio of CD4+/CD8+ in mice injected with MB/virus complexes following US coupled with increased necrosis indicate a successful outcome of the MB/OV treatment that agrees with previous human studies of triple-negative breast cancer [38,40,41]. This evidence concerns the gene CD8A and triple-negative breast carcinoma.